The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).
Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback